Relevant bibliographies by topics / Adjuvant-free

Academic literature on the topic 'Adjuvant-free'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Adjuvant-free.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Adjuvant-free"

1

Conrad, M. L., A. Ö. Yildirim, S. S. Sonar, A. Kılıç, S. Sudowe, M. Lunow, R. Teich, H. Renz, and H. Garn. "Comparison of adjuvant and adjuvant-free murine experimental asthma models." Clinical & Experimental Allergy 39, no. 8 (August 2009): 1246–54. http://dx.doi.org/10.1111/j.1365-2222.2009.03260.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hutchinson, Lisa. "Paclitaxel adjuvant therapy improves relapse-free survival." Nature Reviews Clinical Oncology 6, no. 8 (August 2009): 437. http://dx.doi.org/10.1038/nrclinonc.2009.100.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jones, Rachel S. "Adjuvant imatinib mesylate therapy improves recurrence-free survival." Nature Reviews Gastroenterology & Hepatology 6, no. 6 (June 2009): 320. http://dx.doi.org/10.1038/nrgastro.2009.80.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jin, Yining, Haoran Gao, Rick Jorgensen, Jillian Salloum, Dan Ioan Jian, Perry K. W. Ng, and Venugopal Gangur. "Mechanisms of Wheat Allergenicity in Mice: Comparison of Adjuvant-Free vs. Alum-Adjuvant Models." International Journal of Molecular Sciences 21, no. 9 (May 1, 2020): 3205. http://dx.doi.org/10.3390/ijms21093205.

Full text
Abstract:
Wheat protein is considered a major type of food allergen in many countries including the USA. The mechanisms of allergenicity of wheat proteins are not well understood at present. Both adjuvant-based and adjuvant-free mouse models are reported for this food allergy. However, it is unclear whether the mechanisms underlying wheat allergenicity in these two types of models are similar or different. Therefore, we compared the molecular mechanisms in a novel adjuvant-free (AF) model vs. a conventional alum-adjuvant (AA) model of wheat allergy using salt-soluble wheat protein (SSWP). In the AF model, Balb/cJ mice were sensitized with SSWP via skin exposure. In the AA model, mice were sensitized by an intraperitoneal injection of SSWP with alum. In both models, allergic reactions were elicited using an identical protocol. Robust IgE as well as mucosal mast cell protein-1 responses were elicited similarly in both models. However, an analysis of the spleen immune markers identified strikingly different molecular activation patterns in these two models. Furthermore, a number of immune markers associated with intrinsic allergenicity were also identified in both models. Since the AF model uses skin exposure without an adjuvant, the mechanisms in the AF model may more closely simulate the human wheat allergenicity mechanisms from skin exposure in occupational settings such as in the baking industry.
APA, Harvard, Vancouver, ISO, and other styles
5

Felip, Enriqueta, Rafael Rosell, José Antonio Maestre, José Manuel Rodríguez-Paniagua, Teresa Morán, Julio Astudillo, Guillermo Alonso, et al. "Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer." Journal of Clinical Oncology 28, no. 19 (July 1, 2010): 3138–45. http://dx.doi.org/10.1200/jco.2009.27.6204.

Full text
Abstract:
Purpose To address whether preoperative chemotherapy plus surgery or surgery plus adjuvant chemotherapy prolongs disease-free survival compared with surgery alone among patients with resectable non–small-cell lung cancer. Patients and Methods In this phase III trial, 624 patients with stage IA (tumor size > 2 cm), IB, II, or T3N1 were randomly assigned to surgery alone (212 patients), three cycles of preoperative paclitaxel-carboplatin followed by surgery (201 patients), or surgery followed by three cycles of adjuvant paclitaxel-carboplatin (211 patients). The primary end point was disease-free survival. Results In the preoperative arm, 97% of patients started the planned chemotherapy, and radiologic response rate was 53.3%. In the adjuvant arm, 66.2% started the planned chemotherapy. Ninety-four percent of patients underwent surgery; surgical procedures and postoperative mortality were similar across the three arms. Patients in the preoperative arm had a nonsignificant trend toward longer disease-free survival than those assigned to surgery alone (5-year disease-free survival 38.3% v 34.1%; hazard ratio [HR] for progression or death, 0.92; P = .176). Five-year disease-free survival rates were 36.6% in the adjuvant arm versus 34.1% in the surgery arm (HR 0.96; P = .74). Conclusion In early-stage patients, no statistically significant differences in disease-free survival were found with the addition of preoperative or adjuvant chemotherapy to surgery. In this trial, in which the treatment decision was made before surgery, more patients were able to receive preoperative than adjuvant treatment.
APA, Harvard, Vancouver, ISO, and other styles
6

Eilber, F., A. Giuliano, J. Eckardt, K. Patterson, S. Moseley, and J. Goodnight. "Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial." Journal of Clinical Oncology 5, no. 1 (January 1987): 21–26. http://dx.doi.org/10.1200/jco.1987.5.1.21.

Full text
Abstract:
To determine the role of chemotherapy in the multidisciplinary treatment of patients with osteosarcoma, a randomized prospective trial of postoperative adjuvant chemotherapy was begun in 1981. Fifty-nine patients with nonmetastatic classic intramedullary osteosarcoma were randomized; 32 received postoperative adjuvant chemotherapy consisting of high-dose methotrexate, Adriamycin (Adria Laboratories, Columbus, OH), and BCD (bleomycin, cytoxan, actinomycin D), and 27 patients received no adjuvant chemotherapy. At a median follow-up of 2 years, there was a statistically significant improvement in both disease-free and overall survival in those who received adjuvant chemotherapy. In addition, there was no difference in the less than 20% disease-free or overall survival of patients treated in the 1970s who did not receive chemotherapy, as compared with the concurrent nontreatment controls. Therefore, with identical staging procedures, uniform surgical management, and standard pathologic evaluation, postoperative adjuvant chemotherapy definitely improves disease-free and overall survival in patients with osteosarcoma.
APA, Harvard, Vancouver, ISO, and other styles
7

Logothetis, C. J., D. E. Johnson, C. Chong, F. H. Dexeus, A. Sella, S. Ogden, T. Smith, D. A. Swanson, R. J. Babaian, and K. I. Wishnow. "Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update." Journal of Clinical Oncology 6, no. 10 (October 1988): 1590–96. http://dx.doi.org/10.1200/jco.1988.6.10.1590.

Full text
Abstract:
Seventy-one patients received adjuvant Cytoxan (cyclophosphamide; Bristol-Myers Co, Evansville, IN), Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (CISCA) chemotherapy between March 1981 and March 1986. Patients received adjuvant CISCA chemotherapy if they had pathological findings that were thought to predict for high likelihood of relapse. These included the presence of resected nodal metastases, extravesicular involvement of tumor, lymphatic/vascular permeation of the primary tumor, or pelvic visceral invasion. Sixty-two patients at a similar high risk for recurrence did not receive adjuvant CISCA chemotherapy because they refused, had medical contraindications to therapy, or were not referred for chemotherapy. Two-hundred six patients had a cystectomy performed during the same study period but had none of the poor prognostic features suggesting a high risk for relapse. Sixty-two percent of the patients receiving adjuvant chemotherapy are alive and disease-free for a mean follow-up of 118 weeks (range, 28 to 310 weeks). A survival advantage exists for the adjuvant-treated patients when compared with those with unfavorable pathological findings who did not receive adjuvant chemotherapy (70% v 37%) (P = .00012): no difference exists in long-term disease-free survival for those with favorable pathological findings (long-term disease-free survival 76%) v those who received adjuvant chemotherapy (70%) (P = .33). Adjuvant CISCA chemotherapy prolongs the disease-free survival of some patients following a cystectomy. Patients who benefitted from adjuvant CISCA chemotherapy included those with resected nodal metastases, extra-vesicular involvement of tumor, and direct invasion of the pelvic viscera. Patients not benefitting from adjuvant CISCA chemotherapy in this analysis included those with lymphatic/vascular invasion in their primary tumor as the sole manifestation of high risk for relapse.
APA, Harvard, Vancouver, ISO, and other styles
8

Meyers, Brandon Matthew, Humaid Obaid Al-Shamsi, and Alvaro Tell Figueredo. "Cochrane systematic review and meta-analysis of adjuvant chemotherapy for stage II colon cancer." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 3548. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.3548.

Full text
Abstract:
3548 Background: Colon cancer is potentially curable by surgery in the early stages of the disease. Adjuvant chemotherapy improves disease-free and overall survival in patients with stage III disease, but the magnitude of benefit in stage II colon cancer is less clear. A previous Cochrane systematic review and meta-analysis (SR/MA) found improved disease-free, but not overall survival (Figueredo et al., 2008). An updated SR/MA was performed to determine the effects of adjuvant chemotherapy on disease-free and overall survival in patients with stage II colon cancer. Methods: Relevant databases (MEDLINE, EMBASE, and Cochrane) were independently searched by all authors, using the same search strategy employed in the original study (1/1988 to 9/2012). Randomized trials containing data on stage II colon cancer patients undergoing adjuvant 5-fluorouracil (5FU) chemotherapy versus observation were included. Pooled results were expressed as hazard ratios (HR) whenever possible, or risk ratios (RR), with 95% confidence intervals (95%CI) using a random effects model. Results: Seven studies were identified, and included in the final SR/MA. Six of the 7 studies were included in the disease-free survival analysis (n=4587). Adjuvant 5FU was associated with better disease-free survival (RR 0.84 (95%CI 0.75-0.94)). All 7 studies (n=5353) were included in the overall survival analysis showing an improvement with adjuvant 5FU (HR 0.87 (95%CI 0.78-0.97)). There was no evidence of heterogeneity across the studies (I2 = 0% for all analyses). Conclusions: In stage II colon cancer, adjuvant 5FU chemotherapy statistically improves both disease-free and overall survival. Our SR/MA demonstrates, for the first time, an overall survival advantage with adjuvant chemotherapy in stage II colon cancer.
APA, Harvard, Vancouver, ISO, and other styles
9

Li, Meichen, Xue Hou, Suxia Lin, Lie Zheng, Jianzhong Liang, Jing Chen, Na Wang, Baishen Zhang, and Likun Chen. "Efficacy of adjuvant EGFR inhibitors and impact of clinical factors in resected EGFR-mutated non-small-cell lung cancer: a meta-analysis." Future Oncology 18, no. 9 (March 2022): 1159–69. http://dx.doi.org/10.2217/fon-2021-0934.

Full text
Abstract:
Background: The role of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in resected EGFR-mutated non-small-cell lung cancer (NSCLC) remains unclear. Materials & methods: We evaluated pooled hazard ratio and 95% CI for disease-free survival, overall survival and prespecified subgroups. Results: Seven prospective studies with 1288 patients were included in the meta-analysis. Adjuvant EGFR TKIs significantly improved disease-free survival in EGFR-mutated resected NSCLC (HR: 0.41; 95% CI: 0.24–0.70) and in all subgroups. However, the overall survival benefit was not significant (HR: 0.65; 95% CI: 0.36–1.17). The benefit of adjuvant TKIs may be associated with TKI regimens, treatment duration, pathological stage and EGFR mutation type. Conclusion: Adjuvant EGFR TKIs significantly improved disease-free survival and nonsignificantly improved overall survival in resected EGFR-mutated NSCLC.
APA, Harvard, Vancouver, ISO, and other styles
10

Sakin, Abdullah, Nurgul Yasar, Suleyman Sahin, Serdar Arici, Saban Secmeler, Orcun Can, Caglayan Geredeli, Cumhur Demir, and Sener Cihan. "Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study." Journal of Oncology Pharmacy Practice 26, no. 3 (August 1, 2019): 619–31. http://dx.doi.org/10.1177/1078155219865008.

Full text
Abstract:
Background This study aimed to retrospectively investigate the efficacy and tolerability of adjuvant chemotherapy in ≥70-year-old patients with stage IIA (T3N0M0) colorectal cancer. Methods Lymphovascular invasion, perineural invasion, margin positivity, dissected lymph node count of <12, and presence of perforation/obstruction were accepted as risk factors. Those patients with at least one risk factor were regarded as having high risk. Results The study included 168 patients, among which 95 (56.5%) were male and 73 (43.5%) were female. The median age of patients was 73 years (range: 70–94). One hundred one (60.1%) patients were identified to have high risk. Eighty-one (87%) patients received 5-flourouracil+leucovorin and 12 (13%) patients received capecitabine regimens as adjuvant chemotherapy. The patients receiving capecitabine regimen had significantly higher rates of dose reduction at initiation and during the treatment. Among low-risk group, there was no statistically significant difference between patients with and without adjuvant chemotherapy in terms of disease-free survival or overall survival (p = 0.528 and p = 0.217, respectively). In high-risk group, patients receiving adjuvant chemotherapy significantly differed from those not receiving adjuvant chemotherapy in terms of median disease-free survival and overall survival (p = 0.009 and p < 0.001, respectively). While the grade, lymph node status, and adjuvant chemotherapy were identified as the most significant independent factors for disease-free survival, the most significant factors for overall survival were the age, Eastern Cooperative Oncology Group performance status, adjuvant chemotherapy, and recurrence. Conclusion The findings of our study showed improved disease-free survival and overall survival in high-risk ≥70-year-old patients who received adjuvant chemotherapy due to T3N0M0 colorectal cancer. We believe that 5-flourouracil+leucovorin or capecitabine regimens should be recommended for these older high-risk patients who could receive adjuvant chemotherapy regardless of age.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Adjuvant-free"

1

Chen, Cha-May, and 陳加美. "Designing adjuvant-free vaccine: GnRH vaccine as an example." Thesis, 2011. http://ndltd.ncl.edu.tw/handle/78085824908963614784.

Full text
Abstract:
碩士
國立陽明大學
生化暨分子生物研究所
99
Adjuvant and epitope containing antigen from particular protein of pathogen or self antigens to induced immune response are the two major components of vaccine. Since the epitope alone, a small peptide, usually has poor immunogenicity, adjuvant is needed to enhance the immune response. However, the use of adjuvant always raises unexpected adverse side effects. Thus, the safety issue of using adjuvant is still a major concern in vaccine development. In this study, we develop an adjuvant-free peptide vaccine which comprises with linear epitopes with a carrier protein for delivery to specifically enhance the immunogenicity of the antigen without adding adjuvant. We use GnRH (Gonadotropin-releasing hormone) as our antigen not only because a self antigen with low immunogenicity but also a key hormone that regulate the maturation of sex organ. We designed the immunogen as the Pseudomonas exotoxin receptor–binding domain and 12 copies of GnRH (PE1a-GnRH12) in linear array and immunized with female BALB/C mice 10μg and 20μg respectively. Compare with the adjuvanted GnRH peptide vaccine, after immunization, the adjuvant-free GnRH peptide vaccine resulted in lower Anti-GnRH antibody titer, however, the adjuvant-free GnRH peptide vaccine still manifest reduced the ability of reproduction and degenerated the folliculogenesis in immunized mice. The result indicate, instead using adjuvant, the adjuvant-free GnRH peptide vaccine can be a potential therapeutic application with a safer property. Since the linear polypeptide vaccine may have the risk to generate antibody to junction epitope which can suppress the function of the vaccine or cause undesired immune response, we improve the fusion protein by designing a carrier protein conjugated with GnRH peptides in different ratio to prevent the production of junction epitope in the immunogen. Among different ratio of the carrier protein-GnRH peptide conjugates(referred to GnRH vaccine), the higher ratio of the GnRH vaccine have more GnRH peptide conjugates analyzed by MALDI-TOF. In animal study, the higher GnRH containing vaccine have higher anti-GnRH antibody titer and influence the estrus cycle of the immunized BALB/C mice. The results indicate the GnRH vaccine can be a potential application not only prevent the production of junction epitope but also a platform for different vaccine design.
APA, Harvard, Vancouver, ISO, and other styles
2

Zhang, Bingyang. "Hepatitis B core (HBc) virus like particle (VLP) as a platform for innovation of chimeric adjuvant-free VLP vaccines targeting oncoviruses." Thesis, 2021. http://hdl.handle.net/2440/130894.

Full text
Abstract:
Immunotherapy is an advanced technology for treatment of oncoviruses leading cancers. However, lack of effective and safe vaccines against the oncoviruses has limited the development. This thesis aims to apply Hepatitis B core (HBc) virus like particle (VLP) as a platform for innovation of chimeric adjuvant-free VLP vaccines targeting oncoviruses. Two chimeric HBc VLP-based vaccines presenting Epstein–Barr virus nuclear antigen 1 (EBNA1) epitope (short and non-structural epitope) and Hepatitis C virus (HCV) core epitope (long and structural epitope) were successfully expressed and purified in the Escherichia coli (E. coli) expression system with high production yields, 62.1 mg/g and 40.3 mg/g of wet cell weight, respectively. To further understand and evaluate the influence of insertion of different epitopes to HBc VLP, the stability of chimeric HBc VLP vaccines under different stresses were analysed in comparison with non-chimeric HBc VLP. Computational protein modelling was employed to assist the understanding of the possible cause for the differences. Results indicate that the stability of chimeric HBc VLP vaccines was related to the hydrophobicity of chimeric HBc monomers. The stability of chimeric HBc VLP decreased with the decrease of hydrophobicity of its monomer. This finding would help and improve the efficiency in the development and design of chimeric HBc VLP-based vaccines. In the immunogenicity evaluation, both adjuvant-free EBNA1-HBc VLP and HCV core-HBc VLP induced strong epitope-specific immune response in mice compared with other reported vaccine candidates of EBV and HCV. The achieved immune responses of adjuvant-free EBNA1-HBc VLP and HCV core-HBc VLP groups were comparable to the groups with aluminium adjuvant. No side effect and death of mice were detected during the examination. This confirms that adjuvant-free HBc VLP can present either short non-structured epitope or long structured epitope and can induce strong epitope-specific immune response with low safety risks. Chimeric EBNA1-HBc VLP tended to elicit predominated humoral immune response, while chimeric HCV core-HBc VLP induced predominated cellular immune response. This indicates that the nature of antigens presented by HBc VLP has an impact on the immune response performance, which should be considered in the design of chimeric HBc VLP vaccines in the future. The thesis also found that the addition of aluminium adjuvant would improve the humoral immune response while supressing the cellular immune response of chimeric HBc VLP vaccines. EBNA1-HBc VLP was less affected by the adjuvant on the immune response tendency compared with HCV core-HBc VLP. At last, long-term immunogenicity of two chimeric HBc VLPs were examined by evaluated the epitope specific memory T cells. Both HCV core-HBc VLP and EBAN1-HBc VLP showed good potential for long-term protection. With all above findings, chimeric adjuvant-free HBc VLP-based vaccine is promising to present different types of oncoviruses epitopes with high epitope-specific immune response and low risks. More epitopes targeting different oncoviruses could be presented by chimeric adjuvant-free HBc VLP platform for cancer treatment, and further computational protein modelling is helpful in the design and investigation of these novel chimeric HBc VLP-based vaccines.
Thesis (Ph.D.) -- University of Adelaide, School of Chemical Engineering and Advanced Materials, 2021
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Adjuvant-free"

1

McLeon, Kelly. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. Edited by SreyRam Kuy and Miguel A. Burch. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199384075.003.0011.

Full text
Abstract:
The landmark MOSAIC trial examined whether the addition of oxaliplatin to a postoperative adjuvant treatment regimen of fluorouracil and leucovorin affected disease-free survival from colon cancer. The MOSAIC trial established the efficacy of FOLFOX over 5-FU/LV as adjuvant treatment for stage III colon cancer and established FOLFOX4 as the reference standard for adjuvant treatment for stage III disease. This chapter describes the basics of the study, including funding, year study began, year study was published, study location, who was studied, who was excluded, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. The chapter briefly reviews other relevant studies and information, gives a summary and discusses implications, and concludes with a relevant clinical case.
APA, Harvard, Vancouver, ISO, and other styles
2

Kulkarni, Kunal, James Harrison, Mohamed Baguneid, and Bernard Prendergast, eds. Gastrointestinal and hepatobiliary surgery. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198729426.003.0023.

Full text
Abstract:
Increasing specialization within general surgery has allowed the firm establishment of upper gastrointestinal, colorectal, and hepatobiliary surgery as distinct and separate disciplines. Each subspecialty has evolved and subsequently faced the challenge of improving its outcomes, in the fields of both benign and malignant disease. In cancer treatment, the multidisciplinary approach has developed to become standard, and the evidence base reflects this, now routinely incorporating neoadjuvant and adjuvant oncological treatments, resulting in significant advances in both survival and disease-free survival. This chapter examines the clinical evidence that underpins the main advances in treatment in these three major subspecialties.
APA, Harvard, Vancouver, ISO, and other styles
3

Eisen, Tim. The patient with renal cell cancer. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.

Full text
Abstract:
Renal cancer is the commonest malignancy of the kidney and worldwide, accounts for between 2% and 3% of the total cancer burden. The mainstay of curative treatment remains surgery. There have been significant advances in surgical technique, the most important ones being nephron-sparing surgery and laparoscopic nephrectomy. The medical treatment of advanced renal cell cancer has only improved markedly in the last decade with the development of antiangiogenic tyrosine-kinase inhibitors, inhibitors of mammalian target of rapamycin, and a diminished role for immunotherapy.Tyrosine-kinase inhibitor therapy results in reduction of tumour volume in around three-quarters of patients and doubles progression-free survival, but treatment is not curative. The management of side effects in patients on maintenance tyrosine-kinase inhibitors has improved in the last 3 years, although still presents difficulties which have to be actively considered.The molecular biology of renal cell carcinoma is better understood than for the majority of solid tumours. The commonest form of renal cancer, clear-cell carcinoma of the kidney, is strongly associated with mutations in the von Hippel–Lindau gene and more recently with chromatin-remodelling genes such as PBRM1. These genetic abnormalities lead to a loss of control of angiogenesis and uncontrolled proliferation of tumour cells. There is a very wide spectrum of tumour behaviour from the extremely indolent to the terribly aggressive. It is not currently known what accounts for this disparity in tumour behaviour.A number of outstanding questions are being addressed in scientific and clinical studies such as a clearer understanding of prognostic and predictive molecular biomarkers, the role of adjuvant therapy, the role of surgery in the presence of metastatic disease, how best to use our existing agents, and investigation of novel targets and therapeutic agents, especially novel immunotherapies.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Adjuvant-free"

1

Domenge, C., J. L. Marin, J. P. Droz, F. Eschwege, G. Schwaab, and J. M. Richard. "Post-Radiotherapy Adjuvant Chemotherapy of Regionally Advanced UNPC: Increase in Disease Free Survival." In Epstein-Barr Virus and Human Disease, 491–95. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4590-2_105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hwang, Eugene I., and Roger J. Packer. "Event-Free Survival of Children with Average-Risk Medulloblastoma: Treatment with Craniospinal Radiation Followed by Adjuvant Chemotherapy." In Pediatric Cancer, Volume 4, 93–101. Dordrecht: Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6591-7_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dahm, Philipp. "Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer." In 50 Studies Every Urologist Should Know, 61–66. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190655341.003.0011.

Full text
Abstract:
This chapter summarizes the design, findings, and implications of a landmark trial of adjuvant radiation comparing men who had undergone radical prostatectomy with adverse pathological features (extracapsular tumor extension, positive surgical margins, and/or seminal vesicle invasion) and who were randomized to adjuvant local radiation therapy versus expectant management. Studies results favored adjuvant radiation therapy in terms of both metastasis-free survival and overall survival.
APA, Harvard, Vancouver, ISO, and other styles
4

Madhavan Nair, Lekha, Rejnish Ravi Kumar, Malu Rafi, Farida Nazeer, Kainickal Cessal Thommachan, and Kunnambath Ramadas. "Chemotherapy in Nasopharyngeal Carcinoma." In Pharynx - Diagnosis and Treatment. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.98550.

Full text
Abstract:
Nasopharyngeal carcinoma is a unique disease entity among head and neck cancers due to its epidemiology and clinical behavior. Non-keratinizing or undifferentiated carcinoma is the most common histological type in endemic areas. Radiotherapy is the treatment for early-stage disease. With the widespread use of IMRT, loco-regional control has improved significantly in locally advanced diseases. But distant metastasis continues to be the most common pattern of failure. To address this issue, chemotherapy has been incorporated into radiotherapy in various settings; as concurrent, induction, and adjuvant. The initial trials of concurrent chemotherapy incorporated adjuvant chemotherapy also and the magnitude of benefit contributed by each treatment was not clear. Later trials proved that adjuvant chemotherapy was not beneficial. Induction chemotherapy when added to concurrent chemoradiation resulted in improvement in Failure Free Survival, Overall Survival, and Distant Metastasis Free Survival. Thus, induction chemotherapy followed by concurrent chemoradiation became the standard of care for locally advanced disease (stage III and IVA). The role of chemotherapy in stage II disease is still evolving. Metastatic nasopharyngeal carcinoma is treated by platinum doublet chemotherapy, Cisplatin-gemcitabine is the standard regimen.
APA, Harvard, Vancouver, ISO, and other styles
5

SNIDER, DENIS P. "ADJUVANT-FREE POLYCLONAL ANTIBODY RESPONSE MANIPULATED BY ANTIBODY-MEDIATED ANTIGEN TARGETING." In Antibody Techniques, 49–69. Elsevier, 1994. http://dx.doi.org/10.1016/b978-0-12-466460-9.50006-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McCarville, Justin L., Alberto Caminero, and Elena F. Verdu. "Celiac Treatments, Adjuvant Therapies and Alternatives to the Gluten-Free Diet." In Advances in the Understanding of Gluten related Pathology and the Evolution of Gluten-Free Foods, 223–53. OmniaScience, 2015. http://dx.doi.org/10.3926/oms.254.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sheri, Amna, and Laura Morrison. "Endocrine Treatment of Breast Cancer." In Oxford Textbook of Endocrinology and Diabetes 3e, edited by John A. H. Wass, Wiebke Arlt, and Robert K. Semple, 1782–89. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198870197.003.0220.

Full text
Abstract:
Endocrine manipulation is a well-recognized treatment modality for breast cancer and better understanding of the role of oestrogen in breast cancer pathogenesis has enabled advances in both early and metastatic breast cancer treatment. Two key pathways are used to reduce oestrogen levels—competition for the oestrogen receptor at the cell surface and by reducing peripheral androgen conversion. Adjuvant therapy with the oestrogen receptor antagonist tamoxifen shows improved disease-free and overall survival when given for ten years. Aromatase inhibitors have shown further benefits in the adjuvant setting either alone (in postmenopausal women) or in conjunction with ovarian suppression (in younger, premenopausal women). Endocrine therapy has had a significant impact on breast cancer treatment, but resistance develops in many patients. The mechanisms for this resistance are being investigated and there are a number of emerging treatment options that may help to overcome resistance although this is a complicated area of research.
APA, Harvard, Vancouver, ISO, and other styles
8

Evans, Gregory R. D. "Introduction." In Operative Plastic Surgery, edited by Gregory R. D. Evans, 3–6. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190499075.003.0001.

Full text
Abstract:
Plastic surgery techniques, developed over the preceding 5,000 years, outline the chapters in the second edition of this original book, along with patient considerations. Chapters address the assessment of the defect, the preoperative factors in addressing the problem at hand, the influence of medical or adjuvant therapy, the pathology of the defect, the role of trauma in operative repair, and the correct marriage of donor to recipient tissue. Contributors also address operative indications, operative room setup, and postoperative care and details of pertinent dressings. Plastic surgery has evolved from the transfer of local, pedicle, and free flaps to the understanding of the requirements for angiogenesis and the physiology of tissue molding. Future discoveries will open new avenues for treatment and care.
APA, Harvard, Vancouver, ISO, and other styles
9

Muraleedharan, Amitha, Sagar Kumar, and Rashmi Mittal. "Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future." In Therapeutic Drug Targets and Phytomedicine For Triple Negative Breast Cancer, 73–98. BENTHAM SCIENCE PUBLISHERS, 2023. http://dx.doi.org/10.2174/9789815079784123010007.

Full text
Abstract:
Substantial cohort studies, pre-clinical, clinical trials, and in-depth genomic and proteomic analysis underlie that several molecular alterations exist in TNBC that may be favorable or detrimental to cancer progression. Molecular heterogeneity in TNBC has shortened the disease-free survival rate in response to adjuvant and neoadjuvant therapies. To determine possible vulnerabilities in TNBC, several drugs were under investigation. This chapter highlighted the current paradigm of the therapeutic approach including surgery, radiotherapy, and chemotherapy. In this review, we also highlighted the clinical trials involved in the management of TNBC by targeting angiogenesis, apoptosis, androgen receptors, cell cycle, and pro-survival signalling pathways. To overcome the constraints associated with the mono-therapeutic approach, pre-clinical and clinical studies of combinational therapy have also been discussed to improve OS, DFS, and DMFS in TNBC patients.
APA, Harvard, Vancouver, ISO, and other styles
10

Almefty, Rami O., and Ossama Al-Mefty. "Chordomas and chondrosarcomas of the skull base." In Oxford Textbook of Neurological Surgery, edited by Ramez W. Kirollos, Adel Helmy, Simon Thomson, and Peter J. A. Hutchinson, 189–96. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780198746706.003.0015.

Full text
Abstract:
Chordomas and chondrosarcomas are rare tumours that occur at the skull base. Chordomas have a benign appearing histology but behave malignantly with a high tendency to invade locally, recur, demonstrate tumour progression by accumulating genetic mutations, metastasize, and surgically implant. Aggressive treatment is necessary and radical resection including of the invaded bone followed by adjuvant high-dose radiation therapy offers the best chance for long-term disease-free survival. This requires initiating treatment at the onset, since once the tumour recurs the outcome is poor. Multiple surgical approaches may need to be employed to achieve the sought-after radical resection in a given patient. Utilizing all of the advances in operative techniques including microscopic and endoscopic techniques, intraoperative imaging, and neuronavigation facilitates this goal. Particle-based radiation has a proven record in a large experience as an adjunct to radical surgical resection. Chondrosarcomas are rarer and carry a better prognosis. Complete surgical removal has excellent recurrence-free survival rates. Radiation therapy has also showed high control rates but may not be necessary given their benign course. Immunohistochemical analysis is essential for ensuring the proper diagnosis.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Adjuvant-free"

1

Conrad, ML, AO Yildirim, SS Sonar, A. Kilic, S. Sudowe, M. Lunow, R. Teich, H. Renz, and H. Garn. "The Benefits of the Adjuvant-Free Murine Experimental Asthma Model. Adjuvant and Adjuvant-Free Protocols Produce Similar Phenotypes." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4223.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Franzen, A., M. Färber, S. Strieth, and D. Dietrich. "Cell-free circulating DNA-methylation as biomarker for monitoring adjuvant and palliative immunotherapies." In 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727964.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jain, Vandana, Rupinder Sekhon, Shveta Giri, and Sudhir Rawal. "Role of radical surgery in early stages of vaginal cancer." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685350.

Full text
Abstract:
Objectives: The objective of our present study was to evaluate the efficacy of radical vaginectomy with or without radical hysterectomy in patients with FIGO stage I and II vaginal cancers. Materials and Methods: A retrospective study was carried out on 13 patients aged 35 – 78 years. All the patients underwent radical surgery for vaginal cancer from April 2010 till June 2015. Kaplan- meier analyses was used to calculate the disease free survival and overall survival at 12 months. Results: The mean age of patients was 54.9 years. Twelve patients were with FIGO stage I while one had stage II vaginal cancer. The histopathology was squamous cell cancer in 9 patients, small cell neuroendocrine cancer in two patients and malignant melanoma in 2 patients. The lesion was confined to upper 2/3 of vagina in 8 cases and lower 1/3 was involved in 5 cases. All the patients underwent radical surgery. Lymph node dissection was done in eleven patients out of whom lymph nodes were positive in 4 patients. Three patients had positive margins. Adjuvant treatment was given to patients with positive margins or positive nodes. Six patients did not require any adjuvant treatment and two patients defaulted adjuvant treatment. One patient developed Vesico-vaginal fistula. Over a follow up period ranging from 6 to 67 months, recurrence developed in two patients and one of them died of disease. The 12 months Disease free survival was 82.1% and 12 months Overall Survival was 90.9%. Conclusion: Stage I and selected stage II vaginal cancer patients have good outcomes in terms of survival and local tumor control if managed judiciously by initial surgery followed by selective adjuvant therapy.
APA, Harvard, Vancouver, ISO, and other styles
4

García-González, X., M. Pellicer, MI García, P. García-Alfonso, C. Grávalos, V. Pachón, V. Martinez, P. Martinez-Ortega, M. Sanjurjo, and LA López-Fernández. "PKP-007 Dpyd snps and disease free survival after capecitabine based adjuvant treatment in colorectal cancer." In 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.435.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pitman, NI, GE Murphy, P. Kewin, D. Xu, C. McSharry, NC Thomson, and MC Shepherd. "ST2 Gene-Deletion Attenuates Airways Inflammation and IgE Production in an Adjuvant-Free Model of Asthma." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a2248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dale, Nicole, Kristof Raemdonck, Anthony T. Nials, Maria G. Belvisi, and Mark A. Birrell. "Inflammation And Airway Responsiveness In A House Dust Mite-Driven, Adjuvant-Free Model Of Allergic Asthma." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a2837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Morante, Z., G. De la Cruz-Ku, J. Pinto, J. Araujo, H. Fuentes, D. Enriquez, R. Luque, et al. "Abstract P1-15-02: Benefit of adjuvant chemotherapy in disease-free survival for T1N0 triple negative breast cancer." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p1-15-02.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nakamori, S., N. Miyajima, S. Hyuga, Y. Minami, H. Kazama, M. Hiyama, M. Endo, et al. "Therapeutic and analgesic effects of ephedrine alkaloids-free Ephedra Herb extract on complete Freud’s adjuvant-induced arthritis model mouse." In 67th International Congress and Annual Meeting of the Society for Medicinal Plant and Natural Product Research (GA) in cooperation with the French Society of Pharmacognosy AFERP. © Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-3399686.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Huang, Yu-Hsiang, Pei-Yi Chu, Ji-Lin Chen, Chun-Teng Huang, Chia-Han Lee, Ka-Yi Lau, Wan-Lun Wang, et al. "Abstract 4612: SET overexpression is associated with recurrence-free survival in patients with primary breast cancer receiving adjuvant tamoxifen treatment." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4612.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Reinisch, M., J. O’Shaughnessy, P. Rastogi, S. Johnston, M. Martin, N. Harbeck, M. Toi, et al. "Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib plus adjuvant endocrine therapy for high-risk early breast cancer." In Wissenschaftliche Abstracts zur 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. (DGS) Interdisziplinär. Kommunikativ. Digital. Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1730206.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Adjuvant-free' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography